Shawn W. Sun

机构：Gilead Sciences (United States)

发表论文 9 篇 · 总被引 970 次 · h-index 8

代表论文

• Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results From a Randomized Phase III Trial (2020 · Journal of Thoracic Oncology · 被引 618)
• IMpower131: Primary PFS and safety analysis of a randomized phase III study of atezolizumab + carboplatin + paclitaxel or nab-paclitaxel vs carboplatin + nab-paclitaxel as 1L therapy in advanced squamous NSCLC. (2018 · Journal of Clinical Oncology · 被引 220)
• Important Surgical and Clinical End Points in Neoadjuvant Immunotherapy Trials in Resectable NSCLC (2021 · JTO Clinical and Research Reports · 被引 37)
• Assessing Pathologic Response in Resected Lung Cancers: Current Standards, Proposal for a Novel Pathologic Response Calculator Tool, and Challenges in Practice (2022 · JTO Clinical and Research Reports · 被引 25)
• OptimICE-RD: sacituzumab govitecan + pembrolizumab vs pembrolizumab (± capecitabine) for residual triple-negative breast cancer (2024 · Future Oncology · 被引 23)
• Recent progress in therapeutic antibodies for cancer immunotherapy (2018 · Current Opinion in Chemical Biology · 被引 23)